Clinical practice guidelines for ovarian cancer: an update to the Korean Society of Gynecologic Oncology guidelines

Banghyun Lee; Suk Joon Chang; Byung Su Kwon; Joo Hyuk Son; Myong Cheol Lim; Yun Hwan Kim; Shin Wha Lee; Chel Hun Choi; Kyung Jin Eoh; Jung Yun Lee; Yoo Young Lee; Dong Hoon Suh; Yong Beom Kim

doi:10.3802/jgo.2025.36.e69

Clinical practice guidelines for ovarian cancer: an update to the Korean Society of Gynecologic Oncology guidelines

Banghyun Lee, Suk Joon Chang, Byung Su Kwon, Joo Hyuk Son, Myong Cheol Lim, Yun Hwan Kim, Shin Wha Lee, Chel Hun Choi, Kyung Jin Eoh, Jung Yun Lee, Yoo Young Lee, Dong Hoon Suh, Yong Beom Kim

Department of Obstetrics and Gynecology

Research output: Contribution to journal › Article › peer-review

Abstract

We updated the Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of ovarian cancer as version 5.1. The ovarian cancer guideline team of the KSGO published announced the fifth version (version 5.0) of its clinical practice guidelines for the management of ovarian cancer in December 2023. In version 5.0, the selection of the key questions and the systematic reviews were based on the data available up to December 2022. Therefore, we updated the guidelines version 5.0 with newly accumulated clinical data and added 5 new key questions reflecting the latest insights in the field of ovarian cancer between 2023 and 2024. For each question, recommendation was provided together with corresponding level of evidence and grade of recommendation, all established through expert consensus.

Original language	English
Article number	e69
Journal	Journal of Gynecologic Oncology
Volume	36
Issue number	1
DOIs	https://doi.org/10.3802/jgo.2025.36.e69
State	Published - Jan 2025

Bibliographical note

Publisher Copyright:
© 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic.

Keywords

Hyperthermic Intraperitoneal Chemotherapy
Mirvetuximab Soravtansine
Ovarian Neoplasms
Poly(ADP-ribose) Polymerase (PARP) Inhibitor
Practice Guideline
Risk-educing Salpingo-oophorectomy
Trastuzumab Deruxtecan

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3802/jgo.2025.36.e69

Cite this

Lee, B., Chang, S. J., Kwon, B. S., Son, J. H., Lim, M. C., Kim, Y. H., Lee, S. W., Choi, C. H., Eoh, K. J., Lee, J. Y., Lee, Y. Y., Suh, D. H., & Kim, Y. B. (2025). Clinical practice guidelines for ovarian cancer: an update to the Korean Society of Gynecologic Oncology guidelines. Journal of Gynecologic Oncology, 36(1), Article e69. https://doi.org/10.3802/jgo.2025.36.e69

@article{7773ce207f13440296676aa9f8e90818,

title = "Clinical practice guidelines for ovarian cancer: an update to the Korean Society of Gynecologic Oncology guidelines",

abstract = "We updated the Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of ovarian cancer as version 5.1. The ovarian cancer guideline team of the KSGO published announced the fifth version (version 5.0) of its clinical practice guidelines for the management of ovarian cancer in December 2023. In version 5.0, the selection of the key questions and the systematic reviews were based on the data available up to December 2022. Therefore, we updated the guidelines version 5.0 with newly accumulated clinical data and added 5 new key questions reflecting the latest insights in the field of ovarian cancer between 2023 and 2024. For each question, recommendation was provided together with corresponding level of evidence and grade of recommendation, all established through expert consensus.",

keywords = "Hyperthermic Intraperitoneal Chemotherapy, Mirvetuximab Soravtansine, Ovarian Neoplasms, Poly(ADP-ribose) Polymerase (PARP) Inhibitor, Practice Guideline, Risk-educing Salpingo-oophorectomy, Trastuzumab Deruxtecan",

author = "Banghyun Lee and Chang, \{Suk Joon\} and Kwon, \{Byung Su\} and Son, \{Joo Hyuk\} and Lim, \{Myong Cheol\} and Kim, \{Yun Hwan\} and Lee, \{Shin Wha\} and Choi, \{Chel Hun\} and Eoh, \{Kyung Jin\} and Lee, \{Jung Yun\} and Lee, \{Yoo Young\} and Suh, \{Dong Hoon\} and Kim, \{Yong Beom\}",

note = "Publisher Copyright: {\textcopyright} 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic.",

year = "2025",

month = jan,

doi = "10.3802/jgo.2025.36.e69",

language = "English",

volume = "36",

journal = "Journal of Gynecologic Oncology",

issn = "2005-0380",

publisher = "Korean Society of Gynecologic Oncology and Colposcopy",

number = "1",

}

TY - JOUR

T1 - Clinical practice guidelines for ovarian cancer

T2 - an update to the Korean Society of Gynecologic Oncology guidelines

AU - Lee, Banghyun

AU - Chang, Suk Joon

AU - Kwon, Byung Su

AU - Son, Joo Hyuk

AU - Lim, Myong Cheol

AU - Kim, Yun Hwan

AU - Lee, Shin Wha

AU - Choi, Chel Hun

AU - Eoh, Kyung Jin

AU - Lee, Jung Yun

AU - Lee, Yoo Young

AU - Suh, Dong Hoon

AU - Kim, Yong Beom

PY - 2025/1

Y1 - 2025/1

N2 - We updated the Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of ovarian cancer as version 5.1. The ovarian cancer guideline team of the KSGO published announced the fifth version (version 5.0) of its clinical practice guidelines for the management of ovarian cancer in December 2023. In version 5.0, the selection of the key questions and the systematic reviews were based on the data available up to December 2022. Therefore, we updated the guidelines version 5.0 with newly accumulated clinical data and added 5 new key questions reflecting the latest insights in the field of ovarian cancer between 2023 and 2024. For each question, recommendation was provided together with corresponding level of evidence and grade of recommendation, all established through expert consensus.

AB - We updated the Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of ovarian cancer as version 5.1. The ovarian cancer guideline team of the KSGO published announced the fifth version (version 5.0) of its clinical practice guidelines for the management of ovarian cancer in December 2023. In version 5.0, the selection of the key questions and the systematic reviews were based on the data available up to December 2022. Therefore, we updated the guidelines version 5.0 with newly accumulated clinical data and added 5 new key questions reflecting the latest insights in the field of ovarian cancer between 2023 and 2024. For each question, recommendation was provided together with corresponding level of evidence and grade of recommendation, all established through expert consensus.

KW - Hyperthermic Intraperitoneal Chemotherapy

KW - Mirvetuximab Soravtansine

KW - Ovarian Neoplasms

KW - Poly(ADP-ribose) Polymerase (PARP) Inhibitor

KW - Practice Guideline

KW - Risk-educing Salpingo-oophorectomy

KW - Trastuzumab Deruxtecan

UR - https://www.scopus.com/pages/publications/85217159053

U2 - 10.3802/jgo.2025.36.e69

DO - 10.3802/jgo.2025.36.e69

M3 - Article

C2 - 39900344

AN - SCOPUS:85217159053

SN - 2005-0380

VL - 36

JO - Journal of Gynecologic Oncology

JF - Journal of Gynecologic Oncology

IS - 1

M1 - e69

ER -

Clinical practice guidelines for ovarian cancer: an update to the Korean Society of Gynecologic Oncology guidelines

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this